Bristol-Myers Squibb (BMY) Stock Buyback History
TTM buyback yield 0.08% · Shareholder yield (TTM) 0.08%.
TTM buyback yield
0.08%
Shareholder yield (TTM)
0.08%
5Y share count change
-9.6%
TTM buyback spend
$98.00M
SBC coverage (TTM)
0.18x
YoY change in spend
N/A
5Y CAGR of spend
-100.0%
Peak year (2022)
$8.00B
Cumulative spend
$47.68B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- Bristol-Myers Squibb (BMY) repurchased about $98.00M of stock over the trailing twelve months.
- Diluted share count is down 9.6% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 0.18× — repurchases only partially offset SBC dilution.
- Cash buyback spend has compounded at -100.0% per year over the latest 5-year window.
- TTM repurchases used about 1% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $0.00 | $553.00M | −$553.00M | 2.04B | 0.7% | — |
| 2024 | $0.00 | $507.00M | −$507.00M | 2.03B | -2.5% | — |
| 2023 | $5.16B | $518.00M | $4.64B | 2.08B | -3.2% | 4.96% |
| 2022 | $8.00B | $457.00M | $7.54B | 2.15B | -4.4% | 5.28% |
| 2021 | $6.29B | $583.00M | $5.70B | 2.25B | -0.6% | 4.68% |
| 2020 | $1.55B | $779.00M | $767.00M | 2.26B | 31.9% | 1.11% |
| 2019 | $7.30B | $441.00M | $6.86B | 1.71B | 4.6% | 5.94% |
| 2018 | $320.00M | $221.00M | $99.00M | 1.64B | -0.9% | 0.38% |
| 2017 | $2.47B | $199.00M | $2.27B | 1.65B | -1.7% | 2.46% |
| 2016 | $231.00M | $205.00M | $26.00M | 1.68B | 0.1% | 0.24% |
| 2015 | $0.00 | $235.00M | −$235.00M | 1.68B | 0.5% | — |
| 2014 | $0.00 | $213.00M | −$213.00M | 1.67B | 0.5% | — |
| 2013 | $433.00M | $191.00M | $242.00M | 1.66B | -1.5% | 0.49% |
| 2012 | $2.40B | $154.00M | $2.25B | 1.69B | -1.7% | 4.49% |
| 2011 | $1.22B | $161.00M | $1.06B | 1.72B | -0.6% | 2.05% |
| 2010 | $576.00M | $193.00M | $383.00M | 1.73B | -12.7% | 1.27% |
| 2009 | $0.00 | $183.00M | −$183.00M | 1.98B | -1.1% | — |
| 2008 | $0.00 | $181.00M | −$181.00M | 2.00B | 1.1% | — |
| 2007 | $0.00 | $0.00 | $0.00 | 1.98B | 0.9% | — |
| 2006 | $0.00 | $0.00 | $0.00 | 1.96B | -1.0% | — |
| 2005 | $0.00 | $0.00 | $0.00 | 1.98B | 0.4% | — |
| 2004 | $0.00 | $0.00 | $0.00 | 1.98B | 1.3% | — |
| 2003 | $0.00 | $0.00 | $0.00 | 1.95B | -3.3% | — |
| 2002 | $164.00M | $0.00 | $164.00M | 2.02B | 2.6% | 0.32% |
| 2001 | $1.59B | $0.00 | $1.59B | 1.97B | -1.6% | 1.61% |
| 2000 | $2.34B | $0.00 | $2.34B | 2.00B | -1.5% | — |
| 1999 | $1.42B | $0.00 | $1.42B | 2.03B | -0.2% | — |
| 1998 | $1.56B | $0.00 | $1.56B | 2.03B | -0.5% | — |
| 1997 | $1.16B | $0.00 | $1.16B | 2.04B | 0.3% | — |
| 1996 | $852.00M | $0.00 | $852.00M | 2.04B | — | — |
| 1995 | $244.00M | $0.00 | $244.00M | — | — | — |
| 1994 | $701.00M | $0.00 | $701.00M | — | — | — |
| 1993 | $419.00M | $0.00 | $419.00M | — | — | — |
| 1992 | $228.00M | $0.00 | $228.00M | — | — | — |
| 1991 | $447.00M | $0.00 | $447.00M | — | — | — |
| 1990 | $562.00M | $0.00 | $562.00M | — | — | — |
| 1989 | $51.00M | $0.00 | $51.00M | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Bristol-Myers Squibb (BMY) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Bristol-Myers Squibb (BMY)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Bristol-Myers Squibb (BMY)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $0 | — | $0 | ||
| 2024 | $0 | -100.0% | -$5.16B | ||
| 2023 | $5.16B | -35.6% | -$2.85B | ||
| 2022 | $8.00B | +27.3% | +$1.71B | ||
| 2021 | $6.29B | +306.7% | +$4.74B | ||
| 2020 | $1.55B | -78.8% | -$5.75B | ||
| 2019 | $7.30B | +2181.3% | +$6.98B | ||
| 2018 | $320.00M | -87.0% | -$2.15B | ||
| 2017 | $2.47B | +968.8% | +$2.24B | ||
| 2016 | $231.00M | — | +$231.00M | ||
| 2015 | $0 | — | $0 | ||
| 2014 | $0 | -100.0% | -$433.00M | ||
| 2013 | $433.00M | -82.0% | -$1.97B | ||
| 2012 | $2.40B | +96.8% | +$1.18B | ||
| 2011 | $1.22B | +112.0% | +$645.00M | ||
| 2010 | $576.00M | — | +$576.00M | ||
| 2009 | $0 | — | $0 | ||
| 2008 | $0 | — | $0 | ||
| 2007 | $0 | — | $0 | ||
| 2006 | $0 | — | $0 | ||
| 2005 | $0 | — | $0 | ||
| 2004 | $0 | — | $0 | ||
| 2003 | $0 | -100.0% | -$164.00M | ||
| 2002 | $164.00M | -89.7% | -$1.43B | ||
| 2001 | $1.59B | -32.0% | -$749.00M | ||
| 2000 | $2.34B | +64.8% | +$919.00M | ||
| 1999 | $1.42B | -9.1% | -$142.00M | ||
| 1998 | $1.56B | +34.3% | +$399.00M | ||
| 1997 | $1.16B | +36.4% | +$310.00M | ||
| 1996 | $852.00M | +249.2% | +$608.00M | ||
| 1995 | $244.00M | -65.2% | -$457.00M | ||
| 1994 | $701.00M | +67.3% | +$282.00M | ||
| 1993 | $419.00M | +83.8% | +$191.00M | ||
| 1992 | $228.00M | -49.0% | -$219.00M | ||
| 1991 | $447.00M | -20.5% | -$115.00M | ||
| 1990 | $562.00M | +1002.0% | +$511.00M | ||
| 1989 | $51.00M | — | — |
As of the 2025 fiscal year, Bristol-Myers Squibb (BMY) reported buyback spend of $0.
Through 2020–2025 (5 years), Bristol-Myers Squibb buyback spend delivered a -100.0% annualised rate; with a net decline across the window.
Bristol-Myers Squibb buyback spend peaked at $8.00B in 2022; the latest annual figure is $0 in 2025 (100.0% below peak).
The highest annual buyback spend of $8.00B was reported in 2022. The lowest in the available history was $0 in 2003.
Bristol-Myers Squibb (BMY) sits 8th of 8 Healthcare peers we track on this metric, against a peer median of $2.75B.
Bristol-Myers Squibb Buyback Spend 2025: $0
Bristol-Myers Squibb buyback spend in 2025 was $0.
Bristol-Myers Squibb Buyback Spend 2024: $0
Bristol-Myers Squibb buyback spend in 2024 was $0, plunged 100.0% below 2023.
Bristol-Myers Squibb Buyback Spend 2023: $5.16B
Bristol-Myers Squibb buyback spend in 2023 was $5.16B, plunged 35.6% below 2022.
Bristol-Myers Squibb Buyback Spend 2022: $8.00B
Bristol-Myers Squibb buyback spend in 2022 was $8.00B, grew 27.3% from 2021. This figure represents the highest annual value in the available history.
Bristol-Myers Squibb Buyback Spend 2021: $6.29B
Bristol-Myers Squibb buyback spend in 2021 was $6.29B.
See more financial history for Bristol-Myers Squibb (BMY).
Sector peers by buyback spend
Companies in the same sector as Bristol-Myers Squibb, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.18×.
Capital allocation mix
How Bristol-Myers Squibb splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $6.84B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Bristol-Myers Squibb's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Bristol-Myers Squibb buy back its own stock?
Yes, Bristol-Myers Squibb (BMY) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does Bristol-Myers Squibb spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $98.00M (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is Bristol-Myers Squibb's buyback yield?
TTM buyback yield is about 0.08% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is Bristol-Myers Squibb's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 0.08% combined (TTM-based where available).
Is Bristol-Myers Squibb diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Bristol-Myers Squibb's share count changed?
Diluted weighted average shares changed by about -9.6% over roughly five fiscal years (annual income statement data).
What is Bristol-Myers Squibb's buyback spend?
Latest reported buyback spend for Bristol-Myers Squibb (BMY) is $98.00M (period ending March 31, 2026).
What is the long-term growth rate of Bristol-Myers Squibb buyback spend?
Bristol-Myers Squibb (BMY) buyback spend compound annual growth rate is -100.0% over the most recent 5 years available.
When did Bristol-Myers Squibb buyback spend hit its highest annual value?
Bristol-Myers Squibb buyback spend reached its highest annual value of $8.00B in 2022.
What was Bristol-Myers Squibb buyback spend in 2024?
Bristol-Myers Squibb (BMY) buyback spend in 2024 was $0.
What was Bristol-Myers Squibb buyback spend in 2025?
Bristol-Myers Squibb (BMY) buyback spend in 2025 was $0.
Explore more
BMY Overview
Company profile, financial tools, and key metrics
BMY Revenue Counter
Earns $1,537 every second. See per minute, hour, and day.
BMY Earnings Counter
Earns $230.69 per second net profit. See per minute, hour, and day.
BMY Economic Scale
Exceeds Bahrain's GDP. Compare with world economies.
BMY What If Invested
What if you had invested $1,000? See historical returns from any date.
BMY How It Makes Money
Discover visual breakdown of $48.48B in revenue — where it comes from and where it goes.
BMY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
BMY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
BMY Daily Price Character
Steady · 47.3% historical win rate (green days). Streaks & record days.
BMY Stock Split History
6 splits on record. Dates, ratios, and cumulative multiple.
BMY Dividend Profile
Yield: 4.27%. Safety: 7/8. See full history.
BMY Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
BMY Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
BMY Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
BMY Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.